Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.94 USD | +1.36% | +5.06% | +39.63% |
May. 31 | Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target | MT |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 62
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Matthew Robinson
CTO | Chief Tech/Sci/R&D Officer | 55 | 16-02-29 |
Jack Higgins
CTO | Chief Tech/Sci/R&D Officer | 45 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
Bruce Turner
PRN | Corporate Officer/Principal | 60 | 23-10-01 |
Sandra Stoneman
LAW | General Counsel | 51 | 20-12-09 |
Kinney Horn
PRN | Corporate Officer/Principal | 49 | Jan. 31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
James Boylan
BRD | Director/Board Member | 57 | 23-10-01 |
Isaac Barchas
BRD | Director/Board Member | 56 | 23-10-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,968,868 | 49,724,623 ( 82.92 %) | 0 | 82.92 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.63% | 896M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
+0.09% | 21.96B | |
-8.14% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- IMNM Stock
- Company Immunome, Inc.